News

The company will seek clarification from the FDA of its position and of the additional information required to obtain final marketing approval. UCB confirmed that lacosamide (Vimpat) is

The company has entered into subscription agreements with certain current, new institutional shareholders and affiliates of the company to sell 6.68 million units which are comprised of one

Mr Molloy has 20 years of medical device experience in large corporations and venture funded businesses at the senior management level. He began his career as a certified

This over-the-counter product is used for the reduction and control of gastrointestinal symptoms that are produced by excessive acid secretion and is also helpful in the treatment of

The BrainLAB Monte Carlo dose calculation software is a high performance Monte Carlo algorithm for therapeutic photon beams supporting nearly all linear accelerator and multi-leaf collimator (MLC) types.

The company reported worldwide sales of $5.15 billion in the second quarter of 2008, an increase of 11%, compared with $4.63 billion in the corresponding period of 2007.

The FDA stated that Vanda had demonstrated the effectiveness of iloperidone at 24mg/day in the 3101 study for which the company reported results in December 2006, and that

For the six months ended June 30, 2008, the company reported a net loss of $28.3 million,compared with a net loss of $35.7 million in the same period

The data safety monitoring board meets every six months to review unblinded safety data from the toremifene Phase III clinical trials. Nearly 1,600 patients with high grade prostatic